Nanotechnology-based combination therapy for overcoming multidrug-resistant cancer

作     者：Meng Zhang Ergang Liu Yanna Cui Yongzhuo Huang 

作者机构：Shanghai Institute of Materia MedicaChinese Academy of SciencesShanghai 201203China University of Chinese Academy of SciencesBeijing 100049China State Key Laboratory of Chemical EngineeringSchool of Chemical Engineering and TechnologyTianjin UniversityTianjin 300072China Key Laboratory of Primate NeurobiologyInstitute of NeuroscienceChinese Academy of SciencesShanghai 200031China 

出 版 物：《Cancer Biology & Medicine》 (癌症生物学与医学（英文版）)

年 卷 期：2017年第14卷第3期

页      面：212-227页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：supported by the grants from the National Basic Research Program of China(Grant No.973 Program 2014CB931900,2013CB932503) National Natural Science Foundation of China(Grant No.81373357,81422048,81673382,81521005) 

主　　题：Drug delivery nanotechnology multidrug resistance combination therapy cancer therapy 

摘      要：Multidrug resistance(MDR) is a major obstacle to successful cancer treatment and is crucial to cancer metastasis and relapse.Combination therapy is an effective strategy for overcoming MDR. However, the different pharmacokinetic(PK) profiles of combined drugs often undermine the combination effect in vivo, especially when greatly different physicochemical properties(e.g.,those of macromolecules and small drugs) combine. To address this issue, nanotechnology-based codelivery techniques have been actively explored. They possess great advantages for tumor targeting, controlled drug release, and identical drug PK profiles. Thus,a powerful tool for combination therapy is provided, and the translation from in vitro to in vivo is facilitated. In this review, we present a summary of various combination strategies for overcoming MDR and the nanotechnology-based combination therapy.